pacsin1b Antibody

What is PACSIN1B and how does it relate to PACSIN1?

PACSIN1 (Protein Kinase C and Casein Kinase Substrate in Neurons 1) is primarily expressed in neural tissues and plays crucial roles in synaptic vesicle endocytosis, neuronal development, and neurotransmitter release . It's involved in various cellular processes including endocytosis, membrane trafficking, and cytoskeleton organization . PACSIN1 regulates the reorganization of the microtubule cytoskeleton through its interaction with MAPT (Tau), which decreases microtubule stability and inhibits MAPT-induced microtubule polymerization . While the search results don't specifically differentiate PACSIN1B, it appears to be a variant or isoform of PACSIN1. When designing experiments with PACSIN1B antibodies, researchers should consider the specific epitopes targeted to ensure proper isoform identification.

What are the validated applications for PACSIN1/PACSIN1B antibodies?

Based on available information, the primary validated applications include:

• Western Blotting (WB): Recommended dilution ranges typically from 1:500 to 1:2000 .

• ELISA: Used for quantitative detection of the protein .

• Immunohistochemistry: Successfully employed for visualizing PACSIN1 in tissue sections .

• Immunoprecipitation: Effective for studying protein-protein interactions, particularly with Tau .

When designing experiments, researchers should:

• Use positive control samples (e.g., U-251MG cells for human PACSIN1)

• Include appropriate negative controls

• Optimize antibody concentration for specific tissue or cell types

• Consider the multiple cellular localization patterns expected (cell membrane, cytoplasm, cell junction)

How should I optimize immunohistochemistry protocols for PACSIN1/PACSIN1B detection?

Based on published protocols for PACSIN1 immunohistochemistry:

• Fixation: Use paraformaldehyde or formaldehyde solutions for tissue sections.

• Blocking: Apply appropriate blocking solution to reduce background.

• Primary antibody: For PACSIN1 antibodies, incubate with primary antibody at recommended dilutions.

• Detection method: For fluorescent detection, Alexa Fluor-conjugated secondary antibodies have been successfully used.

• Visualization: Proper imaging and processing are essential for accurate results.

Shimada et al. demonstrated successful PACSIN1 visualization in human tonsil sections using Alexa488-conjugated goat anti-mouse IgG1 secondary antibody, with CD123 co-staining visualized by Alexa549-conjugated streptavidin . Images were acquired using an inverted microscope (BX41, Olympus) with final processing in Photoshop .

What controls should be included when validating a new PACSIN1/PACSIN1B antibody?

When validating a new antibody, incorporate these controls:

• Positive controls:

  • Cell lines known to express PACSIN1 (e.g., U-251MG for human PACSIN1)

  • Brain tissue samples (PACSIN1 is predominantly expressed in brain)

  • Recombinant fusion proteins (such as GST-PACSIN1)

• Negative controls:

  • PACSIN1 knockdown or knockout samples

  • Non-neural tissues (as PACSIN1 is exclusively expressed in brain)

  • Primary antibody omission control

  • Isotype control (using non-specific IgG from the same species)

• Specificity tests:

  • Peptide competition assay using the immunizing peptide

  • Cross-reactivity assessment with other PACSIN family members

The antibody purity should be >95% by SDS-PAGE, as is standard for commercial antibodies .

How can I use PACSIN1/PACSIN1B antibodies to investigate its interaction with Tau in neuronal models?

Based on the research findings of PACSIN1-Tau interactions , implement these methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Lyse neuronal cells or brain tissue in appropriate buffer

  • Perform IP with anti-PACSIN1 antibody

  • Analyze precipitates by Western blot with anti-Tau antibody

  • Perform reciprocal IP with anti-Tau antibody and blot with anti-PACSIN1

• Immunofluorescence co-localization:

  • Fix and permeabilize neurons

  • Co-stain with anti-PACSIN1 and anti-Tau antibodies

  • Analyze co-localization by confocal microscopy

• Yeast two-hybrid assay:

  • Can be used to confirm direct protein-protein interactions

  • Co-expression of TauL4ΔMBD and full-length PACSIN1 yielded positive signals in β-galactosidase assay, confirming direct interaction

Research by Liu et al. demonstrated that PACSIN1 interacts directly with Tau through Pro-434, which is crucial for axonal elongation and branching . PACSIN1 blockade results in impaired axonal elongation and increased primary axonal branching .

What methodologies are effective for studying PACSIN1/PACSIN1B's role in the TLR7/9-mediated type I interferon response?

Based on research by Shimada et al. , implement these approaches:

• Cell isolation and culture:

  • Isolate plasmacytoid dendritic cells (pDCs) using magnetic bead separation or flow cytometry

  • PACSIN1 is specifically expressed in human and mouse pDCs

• Gene silencing approaches:

  • Generate PACSIN1 shRNA constructs (as demonstrated in human pDC cell line)

  • Create PACSIN1-deficient mice (as developed by Shimada et al.)

  • Confirm knockdown efficiency by Western blot

• Stimulation experiments:

  • Treat cells with TLR9 ligands (CpG-A, CpG-B) or TLR7 ligands

  • Challenge with viruses (influenza virus, VSV, HSV-1)

  • Collect supernatants and cell lysates at various time points

• Analysis methods:

  • Measure type I IFN production by ELISA

  • Analyze cytokine production (IFN-α, IL-6, TNF-α)

  • Evaluate PACSIN1 localization during TLR activation

The study showed PACSIN1-deficient pDCs produced significantly less IFN-α compared to wild-type pDCs in response to both CpG-ODN and viruses, while production of other proinflammatory cytokines remained intact .

How can I establish a reliable quantification method for PACSIN1/PACSIN1B expression levels using Western blot?

To establish reliable Western blot quantification:

• Sample preparation:

  • Use appropriate lysis buffer with protease inhibitors

  • Determine optimal protein concentration (typically 20-50 μg total protein)

• Electrophoresis and transfer parameters:

  • Select appropriate percentage gel (10-12% SDS-PAGE for ~50 kDa PACSIN1)

  • Optimize transfer conditions

• Antibody optimization:

  • Determine optimal primary antibody dilution (1:500 to 1:2000 based on manufacturer recommendations)

  • Select appropriate secondary antibody

• Quantification strategy:

  • Use appropriate loading control (e.g., α-Tubulin)

  • Apply linear range detection method

  • Normalize PACSIN1 signal to loading control

What techniques can be employed to investigate PACSIN1/PACSIN1B subcellular localization in neuronal cells?

Based on PACSIN1's reported cellular localization , employ these techniques:

• Immunofluorescence microscopy:

  • Fix neurons with 4% paraformaldehyde

  • Permeabilize with appropriate detergent

  • Incubate with anti-PACSIN1 antibody

  • Co-stain with markers for specific subcellular compartments:

    • Synaptic vesicles

    • Cell membrane

    • Cytoskeletal elements (e.g., α-Tubulin)

• Subcellular fractionation:

  • Prepare neuronal cells or brain tissue

  • Isolate different cellular fractions

  • Analyze fractions by Western blot with anti-PACSIN1 antibody

• Electron microscopy:

  • Prepare samples for immunogold labeling

  • Apply anti-PACSIN1 primary antibody

  • Use gold-conjugated secondary antibody

According to available data, PACSIN1 localizes to multiple cellular compartments including cell junctions, cell membrane, cell projections, cytoplasm, cytoplasmic vesicle membranes, and ruffle membranes . Understanding this localization pattern is crucial for interpreting PACSIN1's functional roles.

What are common issues encountered when using PACSIN1/PACSIN1B antibodies in Western blot analysis and how can they be resolved?

For specific optimization when working with PACSIN1:

• Use brain tissue as positive control (PACSIN1 is exclusively expressed in brain)

• For human samples, U-251MG cells can serve as a positive control

• The expected molecular weight of PACSIN1 is approximately 50 kDa

How can I resolve non-specific binding issues when using PACSIN1/PACSIN1B antibody in immunoprecipitation experiments?

To reduce non-specific binding in immunoprecipitation:

• Pre-clearing the lysate:

  • Incubate cell lysate with beads alone before adding antibody

  • Remove beads by centrifugation

  • This reduces non-specific protein binding to beads

• Optimizing wash conditions:

  • Increase wash number (4-6 washes)

  • Modify buffer stringency (adjust salt concentration)

  • Add mild detergents to wash buffer

• Antibody optimization:

  • Cross-link antibody to beads to prevent heavy/light chain interference

  • Use affinity-purified antibodies for increased specificity (>95% purity)

  • Optimize antibody amount

• Controls to include:

  • IgG control from the same species as the PACSIN1 antibody

  • Lysate from cells with PACSIN1 knockdown

  • Pre-incubation of antibody with immunizing peptide

In published PACSIN1-Tau interaction studies, successful co-immunoprecipitation was achieved using optimized antibody concentrations and wash conditions .

What could explain discrepancies between PACSIN1/PACSIN1B protein expression and mRNA levels in research findings?

Discrepancies between protein and mRNA levels may be attributed to:

• Post-transcriptional regulation:

  • microRNA-mediated regulation of translation

  • RNA-binding protein effects on mRNA stability

  • Alternative splicing leading to different protein isoforms

• Post-translational regulation:

  • Protein degradation via ubiquitin-proteasome system

  • Protein half-life differences

  • Subcellular sequestration

• Technical considerations:

  • Different sensitivities of detection methods (qRT-PCR vs. Western blot)

  • Antibody specificity issues

  • Sample preparation differences

• Analytical approaches to address discrepancies:

  • Measure protein stability using cycloheximide chase assays

  • Investigate translational efficiency

  • Examine potential regulatory factors

Research has shown that PACSIN1 expression increases continuously from embryonic day 14 (E14) to 4 weeks postnatally , suggesting developmental regulation that may involve complex post-transcriptional mechanisms.

How can I distinguish between PACSIN family members (PACSIN1, PACSIN2, PACSIN3) when using antibodies?

To distinguish between PACSIN family members:

• Antibody selection:

  • Choose antibodies raised against unique regions of each PACSIN isoform

  • Verify antibody specificity using recombinant proteins of all PACSIN family members

  • Consider using monoclonal antibodies targeting isoform-specific epitopes

• Validation approaches:

  • Perform Western blot analysis on tissues with known differential expression:

    • PACSIN1: predominantly in brain/neural tissues

    • PACSIN2: more ubiquitously expressed

    • PACSIN3: enriched in muscle and lung

  • Use appropriate control samples

• Complementary techniques:

  • Combine antibody-based detection with PCR using isoform-specific primers

  • Use mass spectrometry to identify specific peptides unique to each isoform

• Experimental controls:

  • Include peptide competition assays with isoform-specific peptides

  • Use recombinant proteins of each isoform as standards

The search results indicate that PACSIN1 is exclusively expressed in brain tissue , which provides a useful reference point for distinguishing it from other PACSIN family members.

How is PACSIN1/PACSIN1B involved in neurological disorders and what methodologies can be used to investigate this connection?

Based on current research findings:

• Disease associations and research approaches:

  Alzheimer's disease:

  • Investigate PACSIN1-Tau interactions in AD models

  • PACSIN1 plays a role in the reorganization of the microtubule cytoskeleton via its interaction with MAPT/Tau

  • Examine effects of PACSIN1 modulation on Tau aggregation

  • Methods: Co-IP, immunohistochemistry, neuronal culture models

  Parkinson's disease:

  • PACSIN1 has been implicated in Parkinson's disease

  • Investigate effects on neuronal function

  • Methods: Neuronal cultures, animal models, protein interaction studies

• Experimental models:

  • Generate PACSIN1-deficient mice (as developed by Shimada et al.)

  • Create neuronal models with PACSIN1 manipulation

  • Analyze post-mortem brain tissue

• Advanced techniques:

  • Protein interaction studies to identify novel binding partners

  • Gene editing to model disease mutations

  • Functional assays to assess impact on neuronal development

The interaction between PACSIN1 and Tau , combined with its role in cytoskeletal organization , suggests potential involvement in tauopathies like Alzheimer's disease.

What are emerging techniques for studying PACSIN1/PACSIN1B protein-protein interactions in living cells?

Advanced techniques for protein interaction studies:

• Yeast two-hybrid assays:

  • Successfully used to confirm direct interaction between PACSIN1 and Tau

  • Enables screening for novel interaction partners

  • Can map specific interaction domains

• Co-immunoprecipitation with advanced detection:

  • Immunoprecipitation followed by mass spectrometry

  • Allows identification of entire interaction networks

  • Can detect transient or weak interactions

• Proximity-based labeling methods:

  • BioID or TurboID approaches

  • APEX2 proximity labeling

  • Identifies proteins in close proximity under physiological conditions

• Fluorescence-based interaction assays:

  • FRET (Förster Resonance Energy Transfer)

  • BiFC (Bimolecular Fluorescence Complementation)

  • Enables visualization of interactions in living cells

The study of PACSIN1-Tau interactions demonstrated that Pro-434 is crucial for this interaction , highlighting the importance of identifying specific binding sites when studying protein-protein interactions.

How can CRISPR-Cas9 gene editing be utilized to study PACSIN1/PACSIN1B function and validate antibody specificity?

CRISPR-Cas9 gene editing offers powerful approaches:

• Antibody validation strategies:

  • Generate PACSIN1 knockout cell lines

  • Confirm absence of protein by Western blot with multiple antibodies

  • Use knockout cells as negative controls in antibody specificity tests

• Functional studies:

  • Create domain-specific mutations

  • Target functional domains (e.g., SH3 domain)

  • Assess effects on known functions (e.g., membrane remodeling, protein interactions)

• Interaction studies:

  • Generate Pro-434 mutants to disrupt Tau interaction

  • Create domain deletions to map functional regions

  • Validate with rescue experiments

• In vivo approaches:

  • Generate more refined knockout models than traditional methods

  • Compare with existing PACSIN1-deficient mice generated through retroviral insertion in the third exon

  • Enable tissue-specific or inducible deletion

These approaches would complement traditional gene knockout strategies as used in PACSIN1 studies , providing more precise control over genetic manipulation.

What are the latest findings on PACSIN1/PACSIN1B in immune cell function and how can researchers investigate this aspect?

Based on findings about PACSIN1 in immune cells :

• Current understanding:

  • Specifically expressed in plasmacytoid dendritic cells (pDCs)

  • Regulates type I interferon (IFN) responses to TLR7/9 stimulation

  • PACSIN1-deficient pDCs show reduced IFN-α production in response to CpG-ODN and viral stimuli

  • Effect is specific to IFN pathway, as proinflammatory cytokine production remains intact

• Research methodologies:

  • Cell isolation techniques to purify pDCs

  • Gene knockdown using shRNA in human pDC cell lines

  • PACSIN1-deficient mouse models

  • Viral challenge experiments (influenza virus, VSV, HSV-1)

• Functional assays:

  • TLR ligand stimulation (CpG-A, CpG-B)

  • Viral infection models

  • Cytokine production measurement (IFN-α, IL-6, TNF-α)

  • In vivo infection studies (HSV-1 infection in mice)

Shimada et al. identified PACSIN1 as a pDC-specific adaptor molecule critical for TLR7/TLR9-mediated type I IFN responses to CpG-ODN and viral stimulation in both human and mouse pDCs .

Future research directions with PACSIN1/PACSIN1B antibodies

Based on current PACSIN1 research, future directions should consider:

• Antibody technology advancements:

  • Development of isoform-specific monoclonal antibodies

  • Generation of phospho-specific antibodies to detect activation states

  • Increased validation standards for research applications

• Emerging research areas:

  • Role in neurodegenerative disease pathways through Tau interaction

  • Function in neuronal development and cytoskeletal organization

  • Contribution to immune system regulation via TLR7/9 signaling in pDCs

• Methodological innovations:

  • Combined proteomic and genetic approaches

  • Advanced imaging techniques for dynamic protein interactions

  • More precise genetic models using CRISPR-Cas9 technology

• Therapeutic potential:

  • Exploration as a target in neurological disorders

  • Investigation of role in interferon-mediated diseases

  • Development of modulators of PACSIN1 function